Search results for "Nap"

showing 10 items of 2226 documents

Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found…

2017

Lung cancer is rich in molecular complexities and driven by different abnormal molecular pathways. Personalised medicine has begun to bring new hope for the treatment of patients with lung cancer, especially non-small cell lung cancer (NSCLC). The development of molecularly targeted therapy (small molecules and monoclonal antibodies) has significantly improved outcomes in the metastatic setting for patients with NSCLC whose tumours harbour activated oncogenes such as epidermal growth factor receptor (EGFR) and translocated genes like anaplastic lymphoma kinase (ALK). In addition, immune checkpoint inhibitors have also dramatically changed the therapeutic landscape of NSCLC. In particular, m…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtymedicine.medical_treatmentPembrolizumabNSCLCTargeted therapy03 medical and health sciences0302 clinical medicinePDL-1/PD-1AtezolizumabInternal medicineMedicineAnaplastic lymphoma kinase1506Epidermal growth factor receptorLung cancerbiologybusiness.industryImmunotherapymedicine.diseaseEditorial030104 developmental biologyOncology030220 oncology & carcinogenesisImmunologybiology.proteinImmune checkpointsImmune checkpointHuman medicineNivolumabbusinessImmune checkpoints; NSCLC; PDL-1/PD-1
researchProduct

Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC

2017

[EN] Background Reported prevalence of driver gene mutations in non-small-cell lung cancer (NSCLC) is highly variable and clinical correlations are emerging. Using NSCLC biomaterial and clinical data from the European Thoracic Oncology Platform Lungscape iBiobank, we explore the epidemiology of mutations and association to clinicopathologic features and patient outcome (relapse-free survival, time-to-relapse, overall survival). Methods Clinically annotated, resected stage I¿III NSCLC FFPE tissue was assessed for gene mutation using a microfluidics-based multiplex PCR platform. Mutant-allele detection sensitivity is¿>1% for most of the ~150 (13 genes) mutations covered in the multiplex test.…

0301 basic medicineOncologyMaleLung NeoplasmsDNA Mutational AnalysisKRAS MUTATIONSGene mutationmedicine.disease_cause0302 clinical medicinemultiplex mutation analysisCarcinoma Non-Small-Cell LungMultiplex mutation analysisPrevalenceMultiplexAnaplastic Lymphoma KinaseHETEROGENEITYAged 80 and overMutationSmokingHematologyMiddle AgedProto-Oncogene Proteins c-metProgression-Free SurvivalOncology030220 oncology & carcinogenesisAdenocarcinomaFemaleKRASPREDICT SURVIVALAdultmedicine.medical_specialtyEGFRCELL LUNG-CANCERPrognosis molecular stagingprognosis molecular stagingEGFR KRAS PIK3CAVALIDATION03 medical and health sciencesYoung AdultInternal medicineMultiplex polymerase chain reactionmedicineKRASTYROSINE KINASE INHIBITORSHumansProgression-free survivalLung cancerAgedNeoplasm Stagingbusiness.industryMICROBIOLOGIAADENOCARCINOMAAMPLIFICATIONPIK3CAmedicine.disease030104 developmental biologynon-small-cell lung cancerMutationOVEREXPRESSIONbusinessMultiplex Polymerase Chain ReactionNon-small-cell lung cancerAnnals of Oncology
researchProduct

A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations

2021

Treatment of advanced non-small cell lung cancer (NSCLC) has radically improved in the last years due to development and clinical approval of highly effective agents including immune checkpoint inhibitors (ICIs) and oncogene-directed therapies. Molecular profiling of lung cancer samples for activated oncogenes, including epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1) and BRAF, is routinely performed to select the most appropriate up-front treatment. However, the identification of new therapeutic targets remains a high priority. Recently, MET exon 14 skipping mutations have emerged as novel actionable oncogenic alterations in NSCLC, sensiti…

0301 basic medicineOncologymedicine.medical_specialtybiologybusiness.industryCancernon-small cell lung cancer (NSCLC)medicine.disease03 medical and health sciencesExon030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesisInternal medicineROS1biology.proteinMET; MET exon 14 skipping mutations; MET-tyrosine kinase inhibitors (TKIs); Non-small cell lung cancer (NSCLC)MedicineAnaplastic lymphoma kinaseEpidermal growth factor receptorbusinessLung cancerTyrosine kinase
researchProduct

IL-33 promotes food anaphylaxis in epicutaneously sensitized mice by targeting mast cells

2016

Background Cutaneous exposure to food allergens predisposes to food allergy, which is commonly associated with atopic dermatitis (AD). Levels of the epithelial cytokine IL-33 are increased in skin lesions and serum of patients with AD. Mast cells (MCs) play a critical role in food-induced anaphylaxis and express the IL-33 receptor ST2. The role of IL-33 in patients with MC-dependent food anaphylaxis is unknown. Objective We sought to determine the role and mechanism of action of IL-33 in patients with food-induced anaphylaxis in a model of IgE-dependent food anaphylaxis elicited by oral challenge of epicutaneously sensitized mice. Methods Wild-type, ST2-deficient, and MC-deficient Kit W-sh/…

0301 basic medicineOvalbuminImmunologyMice TransgenicAdministration CutaneousImmunoglobulin Emedicine.disease_causeArticleDermatitis Atopic03 medical and health sciences0302 clinical medicineAllergenFood allergymedicineAnimalsHumansImmunology and AllergyMast CellsRNA MessengerAnaphylaxisSkinMice Inbred BALB Cbiologybusiness.industryDegranulationAllergensImmunoglobulin EInterleukin-33medicine.diseaseMast cellInterleukin 33Ovalbumin030104 developmental biologymedicine.anatomical_structureImmunologybiology.proteinFemalebusinessFood HypersensitivityAnaphylaxis030215 immunologyJournal of Allergy and Clinical Immunology
researchProduct

Subchronic administration of auranofin reduced amyloid-β plaque pathology in a transgenic APPNL-G-F/NL-G-F mouse model

2020

Abstract Alzheimer’s disease (AD) is the most common cause of dementia. Neuropathological processes, including the accumulation of amyloid-β (Aβ) plaques and neurofibrillary tangles, and neuroinflammation, lead to cognitive impairment at middle and eventually later stages of AD progression. Over the last decade, focused efforts have explored repurposed drug approaches for AD pathophysiological mechanisms. Recently, auranofin, an anti-inflammatory drug, was shown to have therapeutic potential in a number of diseases in addition to rheumatoid arthritis. Surprisingly, no data regarding the effects of auranofin on cognitive deficits in AD mice or the influence of auranofin on Aβ pathology and n…

0301 basic medicinePathologymedicine.medical_specialtyAuranofinGlial fibrillary acidic proteinbiologybusiness.industryAmyloid betaGeneral NeuroscienceGlutamate decarboxylaseHippocampusPathophysiology03 medical and health sciences030104 developmental biology0302 clinical medicineSynaptic plasticitybiology.proteinMedicineNeurology (clinical)businessMolecular Biology030217 neurology & neurosurgeryNeuroinflammationDevelopmental Biologymedicine.drugBrain Research
researchProduct

Contribution of cholesterol and oxysterols to the pathophysiology of Parkinson's disease

2016

International audience; Neurodegenerative diseases are a major public health issue worldwide. Some countries, including France, have engaged in research into the causes of Parkinson's disease, Alzheimer's disease, and multiple sclerosis and the management of these patients. It should lead to a better understanding of the mechanisms leading to these diseases including the possible involvement of lipids in their pathogenesis. Parkinson's disease is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra and the accumulation of α-synuclein (Lewy bodies). Several in vivo studies have shown a relationship between the lipid profile [chole…

0301 basic medicinePathologymedicine.medical_specialtyParkinson's diseaseOxysterolParkinson's diseasePresynaptic TerminalsSubstantia nigraDiseaseBiologyBioinformaticsBiochemistryPathogenesisProtein Aggregates03 medical and health scienceschemistry.chemical_compoundOxysterol0302 clinical medicinePhysiology (medical)medicineHumans[ SDV.BBM ] Life Sciences [q-bio]/Biochemistry Molecular BiologyAlpha-synucleinCell Deathmedicine.diagnostic_testDopaminergic NeuronsMultiple sclerosisParkinson DiseaseOxysterols[ SDV.MHEP.EM ] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismmedicine.diseaseSubstantia NigraCholesterol030104 developmental biologychemistryalpha-Synucleinlipids (amino acids peptides and proteins)Lipid profileOxidation-Reduction030217 neurology & neurosurgeryFree Radical Biology and Medicine
researchProduct

Actinin-4 splice variant - a complementary diagnostic and prognostic marker of pancreatic neuroendocrine neoplasms.

2019

Introduction: For pathological diagnosis of pancreatic neuroendocrine neoplasms (pNENs) the routinely used immunohistochemical markers are chromogranin A (CgA) and synaptophysin (Syn). Their ability as prognostic markers is not well established. A splice variant of actinin-4 (Actn-4sv) was recently found to be an excellent biomarker of neuroendocrine neoplasms of the lung. We aimed to investigate the expression of Actn-4sv in pNENs and evaluate its quality as a biomarker of pNENs. Methods: Paraffin-embedded and frozen tissues specimens from 122 pNENs were analyzed. Western blots were performed to prove and compare the relative amount of Actn-4sv expression in pNENs tissue homogenates. For c…

0301 basic medicinePathologymedicine.medical_specialtysurvival03 medical and health sciences0302 clinical medicinepNENmedicinePathologicalGrading (tumors)Lungbiologybusiness.industryactinin-4 splice variantChromogranin AStainingactinin-4030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisbiology.proteinSynaptophysinImmunohistochemistryLymphbusinessResearch PaperJournal of Cancer
researchProduct

Cytotoxicity and mode of action of a naturally occurring naphthoquinone, 2-acetyl-7-methoxynaphtho[2,3-b]furan-4,9-quinone towards multi-factorial dr…

2017

Abstract Introduction Malignacies are still a major public concern worldwide and despite the intensive search of new chemotherapeutic agents, treatment still remains a challenging issue. The present study was designed to evaluate the cytotoxicity of 2-acetyl-7-methoxynaphtho[2,3-b]furan-4,9-quinone (AMNQ) isolated from the bark of Milletia versicolor towards a panel of drug-sensitive and multidrug-resistant (MDR) cancer cell lines. Methods The resazurin reduction assay was used to evaluate the cytotoxicity of AMNQ against 9 drug-sensitive and multidrug-resistant (MDR) cancer cell lines. Cell cycle, mitochondrial membrane potential (MMP) and levels of reactive oxygen species were all analyze…

0301 basic medicinePharmaceutical ScienceApoptosisPharmacologyFlow cytometry03 medical and health sciences0302 clinical medicineCell Line TumorDrug DiscoverymedicineHumansCytotoxic T cellCytotoxicityMembrane Potential MitochondrialPharmacologymedicine.diagnostic_testPlant ExtractsChemistryCell CycleCancerCell cyclemedicine.diseaseAntineoplastic Agents PhytogenicDrug Resistance MultipleMultiple drug resistance030104 developmental biologyComplementary and alternative medicineDoxorubicinDrug Resistance NeoplasmApoptosisCaspases030220 oncology & carcinogenesisCancer cellCancer researchMolecular MedicineReactive Oxygen SpeciesNaphthoquinonesPhytomedicine
researchProduct

Cocaine-induced changes in CX3CL1 and inflammatory signaling pathways in the hippocampus: Association with IL1β

2020

Cocaine induces neuroinflammatory response and interleukin-1 beta (IL1β) is suggested a final effector for many cocaine-induced inflammatory signals. Recently, the chemokine fractalkine (CX3CL1) has been reported to regulate hippocampus-dependent neuroinflammation and synaptic plasticity via CX3C-receptor 1 (CX3CR1), but little is known about the impact of cocaine. This study is mainly focused on the characterization of CX3CL1, IL1β and relevant inflammatory signal transduction pathways in the hippocampus in acute and repeated cocaine-treated male mice. Complementarily, the rewarding properties of cocaine were also assessed in Cx3cr1-knockout (KO) mice using a conditioned place preference (…

0301 basic medicinePharmacologyChemokinemedicine.medical_specialtybiologyChemistryHippocampusCREBConditioned place preference03 medical and health sciencesCellular and Molecular Neuroscience030104 developmental biology0302 clinical medicineEndocrinologyInternal medicineCX3CR1Synaptic plasticitybiology.proteinmedicineCX3CL1030217 neurology & neurosurgeryNeuroinflammationNeuropharmacology
researchProduct

2018

Haplotypes of the Gabra2 gene encoding the α2-subunit of the GABAA receptor (GABAAR) are associated with drug abuse, suggesting that α2-GABAARs may play an important role in the circuitry underlying drug misuse. The genetic association of Gabra2 haplotypes with cocaine addiction appears to be evident primarily in individuals who had experienced childhood trauma. Given this association of childhood trauma, cocaine abuse and the Gabra2 haplotypes, we have explored in a mouse model of early life adversity (ELA) whether such events influence the behavioral effects of cocaine and if, as suggested by the human studies, α2-GABAARs in the nucleus accumbens (NAc) are involved in these perturbed beha…

0301 basic medicinePharmacologymedicine.medical_specialtyGABAA receptorAddictionmedia_common.quotation_subjectBiologyNucleus accumbens16. Peace & justiceInhibitory postsynaptic potentialMedium spiny neuronmedicine.diseaseSubstance abuse03 medical and health sciencesCellular and Molecular Neuroscience030104 developmental biology0302 clinical medicineEndocrinologyInternal medicinemedicinebiology.proteinGABRA2030217 neurology & neurosurgerymedia_commonGenetic associationNeuropharmacology
researchProduct